ImmunityBio (IBRX) Net Income towards Common Stockholders (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$632.8 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$632.8 million, down 387.89% year-over-year; the trailing twelve-month figure through Mar 2026 was -$854.6 million (down 108.85% YoY), and the FY2025 annual result was -$351.5 million, up 15.03% from the prior year.
• Net Income towards Common Stockholders retreated to -$632.8 million in Q1 2026 per IBRX's latest filing, from -$62.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$59.2 million in Q4 2024 and troughed at -$632.8 million in Q1 2026.
• A 5-year average of -$141.1 million and a median of -$108.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders soared 74.65% in 2024, then plunged 387.89% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$108.3 million in 2022, then slumped by 115.47% to -$233.4 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then fell by 4.7% to -$62.0 million in 2025, then sank by 921.33% to -$632.8 million in 2026.
• Business Quant data shows IBRX's Net Income towards Common Stockholders at -$632.8 million in Q1 2026, -$62.0 million in Q4 2025, and -$67.3 million in Q3 2025.